Spermine Blocks Ferroptosis by Chelating Iron Inside Cells
Scientists discover spermine, a natural polyamine, acts as an internal iron chelator that halts ferroptotic cell death — with implications for cancer and organ protection.
Summary
Researchers publishing in Nature have identified spermine — a polyamine molecule naturally produced in cells — as an endogenous iron chelator capable of directly suppressing ferroptosis, a form of iron-dependent cell death driven by lipid peroxidation. The team found that an enzyme called ALDH18A1 drives a glutamine-dependent pathway that produces spermine, limiting free iron and preventing damaging lipid oxidation in liver cancer cells. Blocking ALDH18A1 genetically or pharmacologically triggered ferroptosis and slowed liver tumor development. On the protective side, supplementing spermine shielded the liver, intestines, and kidneys from ischemia-reperfusion injury. The study reveals a previously unknown metabolic circuit linking polyamine synthesis to iron regulation and cell survival.
Detailed Summary
Ferroptosis — a regulated form of cell death triggered by iron-dependent lipid peroxidation — has emerged as a critical process in aging, cancer, and organ injury. Understanding what naturally keeps ferroptosis in check inside cells has been a major open question in the field. This study addresses that gap by identifying spermine as a previously unrecognized endogenous brake on ferroptotic cell death.
Using an integrated approach combining metabolomics, stable isotope tracing, and biophysical interaction studies, the researchers demonstrated that spermine directly binds ferrous iron (Fe2+), reducing its availability to catalyze lipid peroxidation. The enzyme ALDH18A1 was identified as the key driver of an alternative, glutamine-dependent route to de novo spermine biosynthesis, specifically characterized in hepatocellular carcinoma (HCC) cells.
When ALDH18A1 was knocked out or inhibited — via genetic deletion, AAV-delivered shRNA, or the small-molecule inhibitor YG1702 — spermine levels dropped, iron became more bioavailable, and ferroptosis was triggered. This was sufficient to impair hepatocarcinogenesis in both spontaneous and chemically induced mouse models, suggesting the pathway actively supports tumor survival by suppressing ferroptotic vulnerability.
Conversely, exogenous spermine supplementation protected multiple organs — liver, intestine, and kidneys — from ischemia-reperfusion injury, a clinically common scenario where ferroptosis plays a damaging role. This bidirectional utility positions spermine modulation as a potentially versatile therapeutic lever.
Caveats include that the full paper is behind a paywall, limiting detailed assessment of experimental models and statistical rigor. The translation from mouse cancer models to human disease requires further validation. Additionally, spermine's systemic effects as a polyamine are broad, and off-target consequences of ALDH18A1 inhibition or spermine supplementation in humans remain to be fully characterized.
Key Findings
- Spermine directly chelates Fe2+ ions, reducing iron availability and blocking lipid peroxidation-driven ferroptosis.
- ALDH18A1 drives a glutamine-dependent pathway for de novo spermine synthesis in hepatocellular carcinoma.
- Inhibiting ALDH18A1 with the small molecule YG1702 triggers ferroptosis and suppresses liver tumor growth in mice.
- Spermine supplementation protects liver, intestine, and kidney tissue from ischemia-reperfusion injury.
- A newly identified metabolic circuit links polyamine biosynthesis to iron regulation and cell death control.
Methodology
The study used metabolomics and stable isotope tracing to map spermine biosynthesis, combined with biophysical assays to characterize spermine-Fe2+ binding. In vivo experiments employed genetic knockouts, AAV-delivered shRNA, and pharmacological inhibition in mouse models of liver cancer and organ ischemia-reperfusion injury.
Study Limitations
The study is based primarily on mouse models and cell lines, and human clinical validation is lacking at this stage. Full methodological details are inaccessible due to the paper being behind a paywall. Systemic effects of long-term spermine supplementation or ALDH18A1 inhibition in healthy tissues have not been fully characterized.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: